Monoclonal antibodies in MS Mechanisms of action

被引：77
作者：
Bielekova, Bibiana [1 ]
Becker, Brenda L. [1 ]
机构：
[1] Natl Inst Neurol Disorders & Stroke, Neuroimmunol Dis Unit, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA
来源：
NEUROLOGY | 2010年 / 74卷 / 01期
关键词：
B-CELL DEPLETION; REGULATORY T-CELLS; REMITTING MULTIPLE-SCLEROSIS; NATURAL-KILLER-CELLS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; LYMPHOCYTIC-LEUKEMIA CELLS; CEREBROSPINAL-FLUID; RHEUMATOID-ARTHRITIS; AUTOIMMUNE-DISEASES; RITUXIMAB THERAPY;
D O I：
10.1212/WNL.0b013e3181c97ed3
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The development of monoclonal antibodies (mAbs) presents an emerging, highly specific therapeutic strategy for the treatment of multiple sclerosis (MS). mAbs target selective molecules and have shown early promise, along with notable risks, in the treatment of MS and other immune-mediated diseases. The mechanism of action of the 4 mAbs under active investigation for MS (natalizumab, rituximab, alemtuzumab, and daclizumab) are reviewed, with a discussion of how mAb interaction with each target antigen may produce direct and indirect effects (proven and hypothesized) on immune cell activity, CNS-related inflammatory processes, and clinical outcomes. NEUROLOGY 2010;74 (Suppl 1):S31-S40
引用
收藏
页码：S31 / S40
页数：10
相关论文
共 83 条
  • [1] Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses
    Agarwal, A
    Vieira, CA
    Book, BK
    Sidner, RA
    Fineberg, NS
    Pescovitz, MD
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (08) : 1357 - 1360
  • [2] Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
    Bar-Or, Amit
    Calabresi, Peter A. J.
    Arnlod, Douglas
    Markowitz, Clyde
    Shafer, Stuart
    Kasper, Lloyd H.
    Waubant, Ernmanuelle
    Gazda, Suzanne
    Fox, Robert J.
    Panzara, Michael
    Sarkar, Neena
    Agarwal, Sunil
    Smith, Craig H.
    [J]. ANNALS OF NEUROLOGY, 2008, 63 (03) : 395 - 400
  • [3] Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis
    Bielekova, B
    Catalfamo, M
    Reichert-Scrivner, S
    Packer, A
    Cerna, M
    Waldmann, TA
    McFarland, H
    Henkart, PA
    Martin, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) : 5941 - 5946
  • [4] Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β
    Bielekova, B
    Richert, N
    Howard, T
    Blevins, G
    Markovic-Plese, S
    McCartin, J
    Würfel, J
    Ohayon, J
    Waidmann, TA
    McFarland, HF
    Martin, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (23) : 8705 - 8708
  • [5] Bielekova B, 2009, ARCH NEUROL-CHICAGO, V66, P483, DOI 10.1001/archneurol.2009.50
  • [6] Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab
    Binder, Mascha
    Voegtle, Friederike-Nora
    Michelfelder, Stefan
    Mueller, Fabian
    Illerhaus, Gerald
    Sundararajan, Sangeeth
    Mertelsmann, Roland
    Trepel, Martin
    [J]. CANCER RESEARCH, 2007, 67 (08) : 3518 - 3523
  • [7] CD4+CD25+FOXP3+ regulatory t cells increase De novo in kidney transplant patients after immunodepletion with Campath-1H
    Bloom, D. D.
    Chang, Z.
    Fechner, J. H.
    Dar, W.
    Polster, S. P.
    Pascual, J.
    Turka, L. A.
    Knechtle, S. J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (04) : 793 - 802
  • [8] Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressive in vivo
    Carpenter, PA
    Tso, JY
    Press, OW
    Yu, XZ
    Anasetti, C
    [J]. TRANSPLANTATION PROCEEDINGS, 2000, 32 (07) : 1545 - 1546
  • [9] Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
    Carson, Kenneth R.
    Evens, Andrew M.
    Richey, Elizabeth A.
    Habermann, Thomas M.
    Focosi, Daniele
    Seymour, John F.
    Laubach, Jacob
    Bawn, Susie D.
    Gordon, Leo I.
    Winter, Jane N.
    Furman, Richard R.
    Vose, Julie M.
    Zelenetz, Andrew D.
    Mamtani, Ronac
    Raisch, Dennis W.
    Dorshimer, Gary W.
    Rosen, Steven T.
    Muro, Kenji
    Gottardi-Littell, Numa R.
    Talley, Robert L.
    Sartor, Oliver
    Green, David
    Major, Eugene O.
    Bennett, Charles L.
    [J]. BLOOD, 2009, 113 (20) : 4834 - 4840
  • [10] Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
    Cartron, G
    Dacheux, L
    Salles, G
    Solal-Celigny, P
    Bardos, P
    Colombat, P
    Watier, H
    [J]. BLOOD, 2002, 99 (03) : 754 - 758
123456789